An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

Therapeutic anticancer vaccines are designed to boost patients’ immune responses to tumors. One approach is to use a viral vector to deliver antigen to in situ DCs, which then activate tumor-specific T cell and antibody responses. However, vector-specific neutralizing antibodies and suppressive cell...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Morse, Michael A., Hobeika, Amy C., Osada, Takuya, Berglund, Peter, Hubby, Bolyn, Negri, Sarah, Niedzwiecki, Donna, Devi, Gayathri R., Burnett, Bruce K., Clay, Timothy M., Smith, Jonathan, Lyerly, H. Kim
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2010
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2929723/
https://ncbi.nlm.nih.gov/pubmed/20679728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI42672
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires